Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis?

Infection Control and Hospital Epidemiology

Volumn 36, Issue 3, 2015, Pages 265-272

  Harrison, Michelle ^a   Collins, Curtis D ^a  

^a Saint Joseph Mercy Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROCALCITONIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ARTICLE; BACTERIAL INFECTION; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; NEPHROTOXICITY; QUALITY OF LIFE; SEPSIS; TREATMENT DURATION; ADULT; ALGORITHM; BACTERIAL INFECTIONS; BLOOD; CLINICAL DECISION MAKING; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION STUDY; HOSPITAL COST; HOSPITALIZATION; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; ALGORITHMS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOMARKERS; CALCITONIN; CLINICAL DECISION-MAKING; COST-BENEFIT ANALYSIS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; MODELS, ECONOMIC; PROTEIN PRECURSORS; QUALITY-ADJUSTED LIFE YEARS; SEPSIS; UNITED STATES;

EID: 84923355537     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1017/ice.2014.60     Document Type: Article

References (40)

1. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013;13:426-435
2. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006;34: 1996-2003
3. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008;177:498-505
4. Hohn A, Schroeder S, Gehrt A, et al. Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. BMC Infect Dis 2013;13:158
5. Hochreiter M, Köhler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009;13:R83
6. Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)- guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009;394:221-226
7. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009;34(6):1364-1375
8. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463-474
9. Soni NJ, Samson DJ, Galaydick JL, et al. Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. J Hosp Med 2013;8:530-540
10. Matthaiou DK, Ntani G, Kontogiorgi M, et al. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 2012;38:940-949
11. Prkno A,Wacker C, Brunkhorst FM, Schlattmann P. Procalcitoninguided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and meta-analysis. Crit Care 2013;17:R291
12. Soni NJ, et al. Procalcitonin-guided antibiotic therapy executive summary. Comparative effectiveness review no 78. AHRQ Publication No. 12(13)-EHC124-EF. Rockville, MD: Agency for Healthcare Research and Quality. http://effectivehealthcare.ahrq.gov/ehc/products/219/1274/CER78_Prolactin_ExecutiveSummary_ 20121001.pdf. Published October 2012. Accessed June 14, 2014
13. Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in in the intensive care unit: a randomized trial. Crit Care Med 2011;39:2048-2058
14. Feazel LM, Malhotra A, Perencevich EN, et al. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: A systematic review and meta-analysis. J Antimicrob Chemother 2014;69:1748-1754
15. Smith KJ, Wateska A, Nowalk MP, et al. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. J Gen Intern Med 2013;28:1157-1164
16. Michaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. J Gen Intern Med 2014;29:579-586
17. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011;39:1792-1799
18. Deliberato RO, Marra AR, Sanches PR, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis 2013;76:266-271
19. U.S. Bureau of Labor Statistics. Consumer price index—all urban consumers medical care services. http://www.bls.gov/cpi/data. htm. Published 2014. Accessed June 17, 2014
20. Centers for Medicare & Medicaid Services 2014, Clinical diagnostic laboratory fee schedule. http://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab. html. Published 2014. Accessed June 17, 2014
21. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637
22. Red Book Online. Micromedex 2.0. Thomson Reuters 1974-2012. http://www.thomsonhc.com /micromedex2.com. Published July 2014. Accessed July 10, 2014
23. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-2598
24. Elyasi S, Khalili H, Hatamkhani S, Dashti-Khavidaki S. Prevention of vancomycin induced nephrotoxicity: a review of preclinical data. Eur J Clin Pharmacol 2013;69:747-754
25. Cano EL, Haque NZ, Welch VL, et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACTHAP Database. Clin Ther 2012;34:149-157
26. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013;57: 734-744
27. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16:3365-3370
28. Lucado J, Gould C, Elixhauser A. Statistical brief #124: Healthcare Cost and Utilization Project (HCUP) Clostridium difficile infections (CDI) in hospital stays, 2009. http://hcup-us.ahrq.gov/ reports/statbriefs/sb124.jsp. Published January 2012. Accessed December 12, 2014
29. Fridkin S, Baggs J, Hagan R, et al. Vital signs: improving antimicrobial use among hospitalized patients. MMWR 2104;63:194-200; http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm6309a4.htm?s_cid=mm6309a4_w. Accessed March 25, 2014
30. Angus DC, Linde-Zwirble WT, Clermont G, et al. Costeffectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003;31:1-11
31. Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013;16:297-304
32. Liem YS, Bosch JL, Hunink MG. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health 2008;11:733-741
33. Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med 2012;9: e1001307
34. Elixhauser A, Friedman B, Stranges E. Statistical Brief #122: Septicemia in U.S. Hospitals, 2009. http://www.hcup-us.ahrq. gov/reports/statbriefs/sb122.jsp. Published October 2011. Accessed December 12, 2014
35. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
36. Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012;172:715-722
37. Schuetz P, Raad I, Amin DN. Using procalcitonin-guided algorithms to improve antimicrobial therapy in ICU patients with respiratory infections and sepsis. Curr Opin Crit Care 2013;19:453-460
38. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014;34:670-676
39. Malani AN, Richards PG, Kapila S, et al. Clinical and economic outcomes from a community hospital’s antimicrobial stewardship program. Am J Infect Control 2013;41:145-148
40. Feazel LM, Malhotra A, Perencevich EN, et al. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother 2014;69:1748-1754.